All Merck Articles
Vista Alert: Indaptus Therapeutics Offers Novel Immunotherapy Decoy20 Cancer Treatment Progress Update – $INDP $MRK $NVS $PFE $XBI
Decoy20 represents a novel approach to cancer immunotherapy. Unlike current treatments that target specific immune pathways, Decoy20 aims to activate a broad antitumor response from both innate and adaptive immune systems. Composed of attenuated and killed non-pathogenic Gram-negative bacteria, Deco...
Sep 08, 2024
View Article
Pharma’s Evolving 2024 Acquisition Spree – $ABBV $EPRX $GILD $JNJ $LLY $MRK $NVS $VRTX
Based on reports from The Wall Street Journal, major pharmaceutical companies are shifting their focus to smaller acquisitions in 2024, with all 17 deals announced in the first half of the year valued at $5 billion or less, reflecting a changing regulatory landscape and a more selective approach to ...
Aug 21, 2024
View Article
Merck’s Prevymis Earns European Approval For Kidney Transplant Recipient Care – $MRK $DIA $IBB $LTRN
Reportedly, Merck & Co., Inc. (MRK) announced that the European Union medicines regulator has recommended granting marketing authorization for their medication, Prevymis, aimed at treating a specific infection in adult kidney transplant recipients at a high risk. Furthermore, the Committee for M...
Oct 18, 2023
View Article
Merck Exceeds Revenue Estimates With Strong Sales Of Keytruda & Gardasil In Q2 2023 – $MRK $DIA $IBB $LTRN
Reportedly, Merck & Co., Inc. (MRK) second-quarter revenue exceeded estimates, primarily driven by strong sales of its cancer drug Keytruda and HPV vaccine Gardasil. However, the company swung to a net loss of $5.98 billion, or $2.35 per share, from the previous year's net income of $3.94 billio...
Sep 18, 2023
View Article
Merck Approves $0.73 Per Share Dividend For Q3 2023 – $MRK $DIA $IBB $INVO
As per reports, the board of Merck & Co., Inc. (MRK) announced its quarterly dividend for the third quarter of 2023. The board has authorised a dividend of $0.73 per share for the common stock. Shareholders who are officially listed as such by the end of business on June 15, 2023, will be eligib...
Jun 16, 2023
View Article
Merck’s Q1 2023 Sales & Earnings Call On April 27 – $MRK $DIA $IBB $INVO
Merck & Co., Inc. (MRK) will host a conference call on April 27, 2023 at 9:00 a.m. ET for institutional investors and analysts to discuss the company's sales and earnings for the first quarter. The call will feature an overview of the quarter's performance by company executives. A live audio web...
Apr 04, 2023
View Article
Opko Health Partners with Merck On Epstein-Barr Virus Vaccine Deal Worth Up To $922M – $MRK $OPK $DIA $INVO
As per reports, Opko Health Inc. (OPK) has signed a deal with Merck & Co., Inc. (MRK) for its experimaental Epstein-Barr virus vaccine. Merck will take over the clinical and regulatory activities related to the vaccine, as well as its commercialization once Opko's unit ModeX Therapeutics files...
Mar 13, 2023
View Article
Merck’s Experimental Heart Drugs Show Positive Results (Exercise Capacity) In Clinical Trials – $MRK $DIA $INVO
Merck & Co., Inc. (MRK) has reportedly announced the positive results of a late-stage study revealing that its experimental therapy, sotatercept, has increased the exercise capacity of patients who have a fatal disease that causes high pressure in the blood vessels of the heart and lungs. The ph...
Mar 13, 2023
View Article
Merck Seeks Lynparza’s Expanded Use In Treating Advanced Prostate Cancer – $MRK $DIA $AZN $INVO
Reportedly, Merck & Co., Inc. (MRK) and AstraZeneca PLC (AZN) have announced that an independent advisory committee for the U.S. health regulator will review their application seeking expanded use of Lynparza to treat advanced prostate cancer. The U.S. Food and Drug Administration's committee is...
Mar 07, 2023
View Article
Merck’s COVID Pill Ineffective In Preventing Infection Within Households – $MRK $PFE $DIA $INVO
Reportedly, Merck & Co., Inc.'s (MRK) COVID-19 pill, molnupiravir was not effective at reducing the risk of coronavirus infections in people living with the COVID infected patients. The results were similar to findings from rival Pfizer Inc. (PFE), whose COVID pill Paxlovid also failed to cut ...
Mar 02, 2023
View Article
Merck Records Q4 With Strong Sales In Asia- $MRK $DIA $INVO
Merck & Co., Inc. (MRK) reported strong Q4 earnings as its COVID-19 antiviral pill molnupiravir displayed strong sales in Asia. Merck Chief Executive Rob Davis informed the pandemic wave that moved through Asia in the fourth quarter increased sales of molnupiravir particularly in South Korea, Ja...
Feb 10, 2023
View Article
Global Healthcare Solutions Provider Merck To Pay Q2 Dividend On April 10 – $MRK $DIA $IBB $ATOS
Reportedly, the board of Merck & Co. Inc. (MRK) announced second quarterly dividend of $.73 per share on the company’s common stock payable to stockholders as of March 15, 2023. The dividend is payable on April 10, 2023. Merck & Co., Inc. (MRK) is a global healthcare solutions provider ...
Jan 25, 2023
View Article
Biotech Giant Merck Recognized As One of America’s ‘Most JUST Companies’ By JUST Capital & CNBC – $MRK $DIA $IBB $ATOS
As per reports, Merck & Co., Inc. (MRK) has been named one of America’s Most JUST Companies for the sixth consecutive year, recognized for its commitment to serving its workers, customers, environment, communities, and shareholders. The healthcare giant ranked 26th position overall and secured...
Jan 17, 2023
View Article
Pharmaceuticals Behemoth Merck Schedules Q4 Earnings Release – $MRK $DIA $IBB $XBI $ATOS
As per reports, Merck & Co., Inc. (MRK) is scheduled to host its full-year 2022 and Q4 earnings call on Thursday, February 2 at 8:00 a.m. ET. The call can be reached at weblink. Dial-In : (888) 769-8514 (U.S. Toll-Free) or (517) 308-9208 (International) using the access code 8206435. Merc...
Jan 18, 2023
View Article
Merck Records Best Year Amid Positive Trials & Strong Keytruda Sales – $MRK $DIA $ATOS $INM
Merck & Co., Inc. (MRK) experienced the best yearly gain in 2022 clcking in up 44% making it the top-performing drugmaker. Merck is the maker of the blockbuster cancer drug Keytruda and HPV vaccine Gardasil which has helped boost the company’s solid earnings results. Its Covid-19 therapy Lagev...
Jan 13, 2023
View Article
Merck’s COVID-19 Drug Not Successful In Cutting Hospitalisations? $MRK $DIA $INVO
Reportedly, Merck & Co., Inc. (MRK) COVID-19 antiviral drug, molnupiravir, has been found to accelerate recovery from the virus, but does not reduce hospitalization or death rates in higher-risk, vaccinated adults, according to detailed data from a large study. The drug prevents the virus from r...
Jan 01, 2023
View Article
Indonesia Aims To Combat Growing Cervical Cancer Issues With Merck’s HPV Vaccines – $MRK $DIA $IBB $ATOS
According to the World Health Organization, cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. In Indonesia, the disease took the lives of more than 36,000 people in 2021. Reportedly, Indonesia will produce ...
Dec 18, 2022
View Article
Merck To Pay First-Quarter Dividend On Jan 9 – $MRK $DIA $ATOS $INVO
Reportedly, Merck & Co., Inc. (MRK) is to pay the first quarterly, 2023 dividend of $0.73 per share of the company’s common stock on January 9, 2023. The dividend will be payable to shareholders as of December 15, 2022. Merck & Co., Inc. (MRK) is a global healthcare solutions provider tha...
Dec 04, 2022
View Article
Merck To Acquire Cancer Drug Developer Imago BioSciences For $1.35B – $MRK $DIA $IMGO $ATOS $INVO
Reportedly, Merck & Co., Inc. (MRK) announced the acquisition of Imago BioSciences (IMGO), a cancer drug developer for a total equity value of $1.35B. The company's offer of $36 per share in cash for Imago is nearly a 107% premium to its last closing price. The transaction is expected to close i...
Nov 21, 2022
View Article
Merck & Veeva Extend Their 12-Year Partnership – $MRK $VEEV $ATOS $INVO
Reportedly, Merck & Co., Inc. has recently announced a ten-year strategic partnership agreement with Veeva Systems (VEEV), building on the existing 12-year partnership between the companies. As per the agreement, Merck will take a Veeva-first approach to new industry-specific software and data, ...
Nov 30, 2022
View Article
Merck Board Elects Robert M. Davis As Chairman Succeeding Kenneth C. Frazier – $MRK $DIA $ATOS $INVO
Reportedly, the board of Merck & Co., Inc. (MRK) has announced the election of Robert M. Davis to serve as chairman of the board, effective Dec. 1, 2022, succeeding Kenneth C. Frazier, who is to retire on November 30, 2022, after a long-tenured career at Merck from 1992. Kenneth C. Frazier serve...
Dec 09, 2022
View Article
Moderna & Merck To Develop Cancer Vaccine – $MRNA $MRK $DIA $ATOS $INVO
As per reports, Moderna Inc. (MRNA) and Merck & Co., Inc. (MRK) are considering an option to jointly develop and potentially sell an mRNA-based cancer vaccine. Vaccine mRNA-4157 is being tested along with Keytruda, Merck's blockbuster cancer immunotherapy in a mid-stage trial, and data on the va...
Dec 08, 2022
View Article
Merck Agrees On Distribution Rights For Its COVID-19 Drug With China’s Sinopharm – $MRK $DIA $INVO
As per reports, Merck & Co., Inc. (MRK) has agreed to allow China's Sinopharm to distribute and import its COVID-19 antiviral molnupiravir in China if the drug is approved for use there. The drugmaker has reached a cooperation framework agreement with Sinopharm allowing the Chinese company to di...
Nov 28, 2022
View Article
Merck Schedules Release Of Third-Quarter Earnings – $MRK $DIA $INVO
Reportedly, Merck & Co., Inc. (MRK) is to hold its third-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, October 27. Investors, journalists, and the general public may access a live audio webcast of the call via this link. Me...
Oct 15, 2022
View Article
Merck’s Fiona Marshall To Join Novartis As Research Head – $MRK $DIA $INVO
As per reports, Merck & Co., Inc. (MRK) executive Fiona Marshall has been appointed as president of the Novartis Institutes for Biomedical Research, effective November 1. Marshall will replace Jay Bradner, who is stepping down after seven years as research head. Marshall is currently serving as...
Sep 28, 2022
View Article
Did Merck Stalls Seagen Acquisition Over Price Agreement? – $MRK $DIA $INVO
Reportedly, Merck & Co., Inc.(MRK) talks to buy cancer-drug maker Seagen Inc. has been put on hold for now as the companies have failed to agree on a price, as per sources. In 2020, Merck invested in Seagen as part of a drug partnership and has already tested some of Seagen’s drugs in combinat...
Aug 26, 2022
View Article
Merck’s Quarterly Earnings Beat Estimates Riding Blockbuster Cancer Drug Keytruda Revenues – $MRK $DIA $ATOS
Merck & Co., Inc. (MRK) reported higher-than-expected Q2 earnings and revenue on strong sales of its blockbuster cancer drug Keytruda. Merck reported earnings of $4.74B in the quarter, or $1.87 a share, compared with $1.55 billion, or 61 cents a share, a year earlier. Analysts on average were ex...
Aug 03, 2022
View Article
Merck To Pay Q4 2022 Dividend On Oct 7, 2022 – $MRK $DIA $ATOS
As per reports, the board of Merck & Co., Inc. (MRK) has announced a quarterly dividend of $.69 per share of the company’s common stock for the fourth quarter of 2022. Payment will be made on Oct. 7, 2022, to stockholders as of Sept. 15, 2022. Merck & Co., Inc. (MRK) is a global...
Aug 03, 2022
View Article
Merck Seeking To Close Buyout Of Biotech Company Seagen Inc. – $MRK $SGEN $DIA $ATOS
Reportedly, Merck & Co., Inc. (MRK) is in advanced talks to buy cancer-focused biotech company Seagen Inc. (SGEN) for roughly $40 billion or more. The companies are discussing a price above $200 a share for Seagen. Both the parties are seeking to seal a deal on or before the announcement of Merc...
Jul 14, 2022
View Article
Merck Schedules Release Of Q2 Earnings On July 28 – $MRK $DIA $ATOS
Reportedly, Merck & Co., Inc. (MRK) to host its second-quarter 2022 sales and earnings conference call with the investment community and analysts at 8:00 a.m. ET on Thursday, July 28, discussing Merck’s performance for the quarter and outlook. Web & Call Details: Journalists, Investors, ...
Jul 08, 2022
View Article
Merck Appoints Chirfi Guindo To Lead The Marketing For Merck Human Health – $MRK $DIA
As per reports, Merck & Co., Inc. (MRK) has appointed Chirfi Guindo to lead Human Health Marketing as chief marketing officer for Merck Human Health. Guindo will lead Merck’s Executive Team, effective July 1, 2022, and will report directly to Robert M. Davis, CEO, and president, of Merck. Jann...
Jun 22, 2022
View Article
Merck’s Keytruda & COVID Pill Push Quarterly Beat- $MRK $DIA
Reportedly, Merck & Co., Inc.'s (MRK) quarterly earnings beat estimates reporting a 50% increase in revenue to $15.9 billion with the majority of the growth coming from sales of molnupiravir (approved in November). The drugmaker also raised its full-year forecasts on strong demand for top-sellin...
Apr 29, 2022
View Article
Joseph Romanelli Returns To Merck To Lead Human Health International – $MRK $DIA
Reportedly, Merck & Co., Inc. (MRK) announced that Joseph Romanelli will lead Human Health International, and join Merck’s Executive Team, effective August 1, 2022, and will directly report to Robert M. Davis, chief executive officer, and president, of Merck. In this role, Romanelli will have ...
Apr 20, 2022
View Article
Merck’s Q1 Earnings To Be Released On April 28 – $MRK $DIA
Reportedly, Merck & Co., Inc. (MRK) is scheduled to hold its Q1 2022 earnings conference call with investors and analysts at 8:00 a.m. EDT on Thursday, April 28, discussing the company's performance for the quarter and outlook. Interested parties may access the live audio webcast of the call on ...
Apr 13, 2022
View Article
Merck’s Head Of Global Clinical Development & Chief Medical Officer Dr. Roy D. Baynes Announces Retirement – $MRK $DIA
As per reports, the head of Global Clinical Development (GCD), and Chief Medical Officer, Merck Research Laboratories (MRL) (MRK) , Dr. Roy D. Baynes announces retirement from the position in July. He will be succeeded by Dr. Eliav Barr, effective April 1, 2022. Dr. Baynes will continue to report to...
Mar 24, 2022
View Article
AstraZeneca-Merck’s Lynparza Early-Stage Breast Cancer Drug Gains U.S. FDA Approval – $AZN $MRK $DIA $ATOS
As per reports, the U.S. Food and Drug Administration has approved the cancer drug, jointly developed by Merck & Co., Inc. (MRK) and AstraZeneca Plc. (AZN) as a treatment for patients with early-stage breast cancer with certain mutations. The drug, Lynparza, was approved for patients suffering f...
Mar 15, 2022
View Article
Merck’s COVID-19 Antiviral Pill Receives WHO Recommendation For High-Risk Patients – $MRK $DIA
Reportedly, the World Health Organization (WHO) expert panel has backed the use of Merck & Co Inc's (MRK) COVID-19 antiviral pill for high-risk patients. The expert panel conditionally recommended the pill, molnupiravir, for patients with the non-severe disease with a high risk of hospitalizatio...
Mar 06, 2022
View Article
Merck Announces Exit Of Dr. Julie L. Gerberding, Chief Patient Officer & Executive VP Population Health & Sustainability – $MRK $DIA
Reportedly, Merck & Co., Inc. (MRK) chief patient officer and executive vice president, population health and sustainability, Dr. Julie L. Gerberding, to retire from the company in May 2022. Dr. Gerberding to join as CEO of the Foundation for the National Institutes of Health (FNIH) on May 16. ...
Mar 03, 2022
View Article
Merck Announces 3 New Leadership Appointments For Its Human Health Business – $MRK $DIA
As per reports, Merck & Co., Inc. (MRK) announced three new leadership for its Human Health business, effective Feb. 28, 2022. Arpa Garay will lead Human Health Global Marketing, Jannie Oosthuizen will lead Human Health U.S., and the company is recruiting externally to fill the Human Health Inte...
Feb 23, 2022
View Article
Merck To Discuss Its ESG Priorities On Feb 23
As per reports, Merck & Co., Inc. (MRK) is scheduled to hold a virtual Investor Event where its senior management team will discuss Environmental, Social & Governance (ESG) priorities on Wednesday, February 23 at 10:00 a.m. EST. The webcast can be reached by analysts, investors, members of t...
Feb 17, 2022
View Article
Merck Releases Q4 Earnings Stays Bullish On COVID-19 Pill Sales – $MRK $DIA
Reportedly, Merck & Co., Inc. (MRK) released fourth-quarter earnings recently. They confirmed that they expecting its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir. The drugmaker also informed that the sales of the COVID-19 dr...
Feb 06, 2022
View Article
Merck Announces Exit Of Executive VP & President For Human Health, Frank Clyburn – $MRK $DIA
Reportedly, Frank Clyburn, executive vice president, and president, Human Health, to leave Merck & Co., Inc. (MRK) on Feb. 1, 2022, and continue with leadership opportunity in another company. Clyburn joined Merck in 2008 and held several leadership positions with increasing responsibility throu...
Jan 25, 2022
View Article
U.N.-backed Medicines Patent Pool (MPP) Enterd Deal To Produce Low-Cost Versions Of Merck’s COVID-19 Pill- $MRK $DIA
As per reports, the U.N.-backed Medicines Patent Pool (MPP) has entered a deal with nearly 30 generic drugmakers to make low-cost versions of Merck & Co's., Inc. (MRK) COVID-19 pill molnupiravir for poorer nations, allowing access to the drug globally. As per the clinical trial results, the anti...
Jan 24, 2022
View Article
Merck To Supply 3M Courses Of COVID-19 Antiviral Pill To UNICEF – $MRK $DIA
As per reports, Merck & Co., Inc. (MRK) and partner Ridgeback Biotherapeutics have entered an agreement with the United Nations Children's Fund (UNICEF) to supply up to 3 million courses of their COVID-19 antiviral pill. Merck would supply the pill, molnupiravir, to UNICEF through the first hal...
Jan 20, 2022
View Article
Merck Schedules Fourth-Quarter & Full-Year 2021 Earnings Call On February 3 – $MRK $IBB
Reportedly, Merck & Co., Inc. (MRK) to host its fourth-quarter and full-year 2021 sales and earnings conference call with institutional investors and analysts on Thursday, Feb. 3. at 8:00 a.m. EST. Link & Call Details: Interested parties can reach a live audio webcast of the call on Merck...
Jan 11, 2022
View Article
Merck’s Antiviral Covid-19 Pill Gets Approval In Japan
As per reports, the Japanese health ministry panel has approved the use of the COVID-19 antiviral pill, molnupiravir developed by Merck & Co., Inc. (MRK) as a part of Prime Minister Fumio Kishida's plan to roll out new treatments by year-end amid growing concerns for the rising Omnicron variant....
Dec 29, 2021
View Article
EU’s Regulator Expected To Reveal ‘Opinion’ On Merck’s COVID Pill ‘Within Weeks’
Reportedly, the European Union's drug regulator has started reviewing U.S. drugmaker Merck & Co Inc's (MRK) experimental COVID-19 antiviral pill for adults following an application and is expected to issue an opinion "within weeks." In October, the European Medicines Agency has already evaluated...
Dec 01, 2021
View Article
Merck’s Acquisition Of Acceleron Pharma Inc. Finalized
Reportedly, Merck & Co., Inc. (MRK) has completed the acquisition of Acceleron Pharma Inc, a public American "clinical stage biopharmaceutical company" building on mobilizing the power of the transforming growth factor (TGF)-beta superfamily of proteins that plays a key role in the regulation of...
Nov 24, 2021
View Article
Merck Reportedly Advancing Talks With European Union With Regard To Covid-19 Pills
Reportedly, the European Union is negotiating with Merck & Co., Inc. (MRK) and Pfizer over possible contracts to supply their experimental COVID-19 drugs. Both the healthcare giants have developed antiviral pills that have shown promising efficacy in adults displaying Merck's efficacy result of ...
Nov 10, 2021
View Article
Merck Reports Quarterly Earnings Beat- Raises Outlook Point Toward Covid-19 Antiviral Molnupiravir Pill Sales
As per reports, Merck & Co., Inc. (MRK) is riding high on its Covid-19 antiviral molnupiravir that is expected to bring in as much as $7 billion in global sales through 2022, the figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December. Merck’s M...
Nov 01, 2021
View Article
Merck Appoints Board Member Thomas H. Glocer As Independent Lead Director Effective Immediately
Reportedly, the board of Merck & Co., Inc. (MRK) announced the appointment of Thomas H. Glocer as independent lead director effective immediately. Mr. Glocer has served on the Merck Board of Directors since 2007 and has extensive management, technology, operational, and international business ex...
Sep 30, 2021
View Article
Merck’s Oral COVID-19 Antiviral Drug Showing To Be Efficacious Against Variants
Reportedly, Merck & Co., Inc.'s (MRK) experimental oral COVID-19 antiviral drug, molnupiravir is expected to produce promising results against variants of the coronavirus, including the dominant, highly transmissible Delta. Molnupiravir does not target the spike protein of the virus, which all ...
Oct 01, 2021
View Article
Reportedly, Merck Expected To Close $11B Deal With Blood-Related Disorder Therapeutics Firm Acceleron Pharma
Reportedly, Merck & Co., Inc. (MRK) is in advanced talks to acquire drugmaker Cambridge, Massachusetts-based, Acceleron Pharma Inc (XLRN) . Acceleron is focused on the discovery, development, and commercialization of therapeutics to treat blood-related disorders. As per a Bloomberg report, ...
Sep 28, 2021
View Article
Merck Begins Enrolling Patients In A Late-Stage Trial Of Its COVID-19 Experimental Drug Molnupiravir
Reportedly, Merck & Co., Inc. (MRK) and partner Ridgeback Biotherapeutics have begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for the prevention of COVID-19 infection. The drug will be administered and studied in over 1,300 volunteers to determine if it ca...
Sep 02, 2021
View Article
Merck Ranks First On The List Of 60 Best Large Workplaces In New York By Fortune
As per reports, Merck (MRK) has ranked first of 60 companies on the 2021 list of the 60 Best Large Workplaces in New York compiled by Great Place to Work, Fortune's research partner. Merck has been appreciated for supportive cultures, where employees find opportunities for growth and help from their...
Aug 22, 2021
View Article
Merck Ranked #1 In Forbes’ 2021 List of ‘Best Employers For New Graduates’
Reportedly, Merck & Co., Inc. (MRK) has been named #1 'Best Employers For New Graduates' as identified by the Forbes team along with market research company Statista. The survey was conducted to identify the companies most liked by new workforce entrants in their annual ranking. The list surv...
Aug 05, 2021
View Article
Merck Appoints Cristal N. Downing To Newly Created Role Of Chief Communications & Public Affairs Officer
As per reports, Merck & Co., Inc. (MRK) has appointed Cristal N. Downing as the chief communications & public affairs officer, a newly created role, effective August 16, 2021. Downing will lead the advancement, development, and execution of the company’s communications and public affairs s...
Jul 31, 2021
View Article
Merck Beats Q2 Estimates – Keytruda Growth Remains Strong
Merck & Co., Inc. (MRK) reported quarterly revenue beating Wall Street's estimates, as sales for its blockbuster cancer drug Keytruda remained strong and demand for its Gardasil vaccine also rebounded. The company's second-quarter sales increased 22% to $11.40 billion, beating estimates of $11.1...
Jul 30, 2021
View Article
Merck’s Keytruda Approved By U.S. FDA To Treat Early Breast Cancer In Combo With Chemotherapy
Reportedly, U.S FDA has granted approval to Merck & Co Inc.’s (MRK) immunotherapy Keytruda for the treatment of an early form of breast cancer, used in combination with chemotherapy. The U.S. Food and Drug Administration's approval is for the treatment of triple-negative breast cancer (TNBC),...
Aug 02, 2021
View Article
Merck Enters Supply Agreement With U.S. Government For Investigational Oral Antiviral Candidate For COVID-19
Reportedly, Merck & Co., Inc. (MRK) has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). Molnupiravir is under Phase 3 clinical trial, the MOVe-OUT study for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at lea...
Jun 13, 2021
View Article
Merck Completes Spinoff Of Organon & Co. Aiming To Create 2 patient-focused Companies
Reportedly, Merck & Co., Inc. (MRK) has completed the spinoff of Organon & Co. The spinoff aims to create two patient-focused companies with an enhanced strategic and operational focus, simplified operating models, improved agility, improved financial profiles, and optimized capital struct...
Jun 04, 2021
View Article
Merck & Sanofi Has Developed First Hexavalent Combination Vaccine Vaxelis™ In US
Reportedly, Merck & Co., Inc. (MRK) has developed a hexavalent combination vaccine Vaxelis™ in partnership with Sanofi Pasteur, the global vaccines business unit of Sanofi. Vaxelis will be widely available in the U.S. via traditional private and public channels, including directly from Sanof...
Jun 01, 2021
View Article
Merck Announces Q3 2021 Dividend Payable July 7, 2021.
Reportedly, Merck & Co., Inc. (MRK) has announced a quarterly dividend of $0.65 per share of the company’s common stock for the third quarter, 2021 to shareholders of record at the close of business on June 15, 2021. The dividend is payable on July 7, 2021. Merck & Co., Inc. (MRK) is ...
May 30, 2021
View Article
Merck Reports Disappointing Profits In Q1
Merck & Co. Inc. (MRK) reports disappointing Q1 profit figures, hurt by the low demand for drugs that need to be administered at a doctor's office, as the pandemic fear continued. The company informed that two-thirds of its treatments and vaccines need to be administered by a doctor, usage of...
Apr 29, 2021
View Article
Merck Partners With Indian Generic Drugmakers For COVID-19 Drug Production & Access To Molnupiravi
Reportedly, Merck & Co., Inc. (MRK) has partnered with five Indian generic drugmakers, including Sun Pharmaceutical Industries Ltd & Cipla Ltd, to expand production and access to its experimental COVID-19 drug, molnupiravir. The partnership will allow the companies with licenses to supply...
Apr 27, 2021
View Article
Merck Acquires Pandion Therapeutics
As per reports, Merck & Co., Inc. (MRK) has completed the acquisition of Pandion Therapeutics, Inc, for all of the outstanding shares of the common stock of Pandion Therapeutics, Inc at $60 per share through a subsidiary after successful completion of the cash tender offer. Pandion is set to bec...
Apr 07, 2021
View Article
Merck’s Spinoff Unit Organon To Acquire Alydia Health – Medical Device Co. Focused on Preventing Maternal Mortality
As per reports, Merck & Co., Inc.(MRK) Inc. has entered into a definitive agreement with Alydia Health, following the spinoff of its women’s health under the new company, Organon. Organon, a global healthcare company will acquire Alydia Health, focusing on improving the overall health of women...
Mar 31, 2021
View Article
Merck Announces Q1 2021 Sales & Earnings Release & Conference Details – April 29
As per reports, Merck & Co., Inc. (MRK). is set to host its first-quarter 2021 earnings conference call at 8:00 a.m. ET on Thursday, April 29. The live call webcast can be reached on the company’s website under “Events & Presentation”. Investors and analysts can dial (833) 353-0277 o...
Apr 07, 2021
View Article
EMA Issues Warnings Against The Use Of Merck’s Anti-Parasite Drug For COVID-19
As per reports, the European Medicines Agency has issued warnings against the use of ivermectin, Merck & Co's (MRK) anti-parasite drug for the prevention or treatment of COVID-19 outside clinical trials. A similar warning was also issued from the U.S. Food and Drugs Administration stating, as p...
Mar 22, 2021
View Article
Merck Stocks Rise As Its Oral Antiviral Treatment Shows Promising Results
Reportedly, Merck & Co., Inc. (MRK) stocks soared after its Ridgeback Biotherapeutics-partnered Covid-19 treatment known as molnupiravir displayed promising results in an interim analysis of a Phase 2. Merck stock recently slipped this year after the company scrapped the development of two "i...
Mar 10, 2021
View Article
Merck To Assist In Production Of J&J’s Single-Dose COVID-19 Vaccine, Snags Funds From BARDA To Expand Facilities
Reportedly, Merck & Co., Inc. (MRK) has entered into multiple agreements to expand and support the manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. BARDA, the Biomedical Advanced Research and Development Authority, a unit of the Office of the Assistant Secret...
Mar 03, 2021
View Article
Merck Releases Q4 Earnings Below Estimates
Merck & Co. Inc. (MRK) reports disappointing quarter results with coronavirus pandemic impacting $400 million on fourth-quarter sales. Sales increased 5% to $12.51 billion but missed analyst forecasts for $12.67 billion. Adjusted earnings came in at $1.32 per share missing estimates of $1.38 p...
Feb 08, 2021
View Article
Merck CEO, Kenneth C. Frazier To Step Down – Board Elects CFO Robert M. Davis As Successor
As per reports, Merck & Co., Inc. (MRK) chairman and chief executive officer, Kenneth C. Frazier will retire as CEO, effective June 30, 2021, but will continue to serve on Merck’s board of directors as executive chairman, for a transition period yet to be determined by the board. The board o...
Feb 09, 2021
View Article
Merck Schedules February 4 To Release Its Financial 2020 Results
Reportedly, Merck & Co., Inc. (MRK) to review and discuss its full-year and fourth quarter 2020 financial results on Thursday, Feb. 4 at 8:00 a.m. ET. Interested parties can reach the live audio webcast of the event at the company’s website under “Events & Presentation”. A replay ver...
Jan 12, 2021
View Article
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
